Fortune 500 pharmaceutical company

January 1, 1990

Representation of a Fortune 500 pharmaceutical company in connection with its acquisition of a diagnostic substance and chemical manufacturer, pursuant to a reverse triangular merger. Total consideration was approximately $135 million.
Back to top